References
- Haddad PM, Anderson IM: Antipsychotic related QTc prolongation, TdP and sudden death. Drugs 2002; 62(11):1649–71.
- US Food and Drug Administration. July 19, 2000 US FDA. Center for Drug Evaluation and Research. Brief-ing Information for Psychopharmacologic Drugs Advi-sory Committee Meeting. http://www.fda.gov/ohrms/ dockets/ac/00/backgrd/3619b1.htm
- Harrigan, EP, et al: A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharm 2004; 24:1:62–69.
- Keck PE, McElroy SL: Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002; 63\(supp4):3–11.
- AstraZeneca, Inc. (2003): Seroquel (quetiapine fuma-rate) prescribing information, Rev 7/03.
- Bednar, et al: The QT interval. Prog Cardiovasc Dis 2001; 43:1–45.
- Elming H, et al: QTc interval in the assessment of cardiac risk. Card Electrophysiol Rev 2002 Sept 6; 3: 289–94.
- Gajawani P. et al: QT interval prolongation associated with quetiapine (seroquel) overdose. Psychosomatics 2000 Feb; 41:63–65.
- Beelen AP, et al: Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Human and Experimental Toxicology 2001; 20:215–219.
- Gupta S, et al: quetiapine and QTc issues: A case report. J Clin Psychiatry May 2003; 64:5:612–613.